Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sorrento Therpt (NQ: SRNE )

2.130 -0.390 (-15.48%)
Streaming Delayed Price Updated: 11:58 AM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,465,544
Open 2.500
Bid (Size) 2.130 (41)
Ask (Size) 2.140 (213)
Prev. Close 2.520
Today's Range 2.060 - 2.510
52wk Range 1.150 - 9.630
Shares Outstanding 449,952,163
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
10 Stocks to Sell Before They Die
As the U.S. continues to struggle with stagflation, it’s becoming more important than ever to avoid pitfalls. 
Via InvestorPlace
FDA Clears Sorrento's STI-1558 Phase 1 Study To Treat COVID-19 Infection
 
Via Benzinga

Performance

YTD
-56.53%
-56.53%
1 Month
-13.77%
-13.77%
3 Month
+35.67%
+35.67%
6 Month
-31.73%
-31.73%
1 Year
-75.06%
-75.06%

More News

Read More
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
Via Benzinga
Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
FDA Gives Green Signal To Human Trial For Sorrento's STI-9167 Against Omicron
Via Benzinga
Sorrento Shares Gain Following FDA's Nod for Initial-Stage Covid-19 Study
Via Benzinga
Epizyme + 20 Stocks Moving In Monday's Pre-Market Session
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Sorrento To Start Late-Stage Trial Of Abivertinib In Critically-Ill COVID-19 Patients
Via Benzinga
The Biotech Company That's Training Immune Cells To Fight Cancer
Via Benzinga
Sorrento's Chimeric mRNA COVID-19 Vaccine Candidate Shows Preclinical Action Against Omicron Variants
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Via Benzinga
Sorrento's Scilex Unit Begins Mid-stage Study of Lower Back Pain Drug
Via Benzinga
67 Biggest Movers From Yesterday
Via Benzinga
Sorrento Therapeutics shares are trading high following FDA clearance of IND for Abivertinib in metastatic castrate resistant prostate cancer (mCRPC)
Via Benzinga
71 Biggest Movers From Yesterday
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
10 Biggest Price Target Changes For Friday
Via Benzinga
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
Via FinancialNewsMedia
Exposures COVID-19
The Week In SPAC News: Digital World Under Pressure As Truth Social Rank Slides
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.